Drug Candidate for Treatment of Pulmonary Arterial Hypertension
Ralinepag (APD811), an orally available agonist of the prostacyclin (IP) receptor, is an investigational drug candidate internally discovered and developed by Arena. Ralinepag’s potent actions on pulmonary vascular smooth muscle cells and platelets, combined with an optimized pharmacokinetic profile support its intended use for the treatment of vasospastic diseases, such as Pulmonary Arterial Hypertension.
About Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension (PAH) is a progressive, life-threatening disorder characterized by increased pressure in the arteries that carry blood from the heart to the lungs. The increased pressure strains the heart, which can limit physical activity, result in heart failure and reduce life expectancy. Based on data from the Registry to EValuate Early And Long-term PAH disease management (REVEAL) of patients in the United States, there is an estimated five-year survival rate of 57% from diagnosis.
We have initiated a randomized, double-blind and placebo-controlled Phase 2 clinical trial to evaluate the hemodynamic and exercise capacity effects, safety and tolerability of ralinepag. Visit our Clinical Trials page for more information.
|Drug Candidate||Disease Area||Target||Status||Retained Rights|
|Ralinepag (APD811)||Pulmonary Arterial Hypertension||IP Receptor Agonist||Phase 2 Trial Ongoing||Worldwide|
|Drug Candidate||Ralinepag (APD811)|
|Disease Area||Pulmonary Arterial Hypertension|
|Target||IP Receptor Agonist|
|Status||Phase 2 Trials Ongoing|
Ralinepag has not been approved by the US Food and Drug Administration or any other regulatory agency.